JWH-133
JWH-133 has been studied in 2 papers since 2016: none in people yet, 1 in animals, 1 review. The research so far is in animals. The newest paper, Jul 29, 2021: “Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases”.
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
- 1 lab in 1 country
- Funders: Brain & Behavior Research Foundation and 7 more
- Animals1
What did studies of JWH-133 find?
4Studies of JWH-133 measured 4 outcomes, among them neurogenesis, inflammation and neuronal oxidative damage.
neurogenesis
upin reviews1
1 study
neurogenesis
upin reviews1
JWH-133 increases neurogenesis.
“JWH133 showed to protect neurons from oxidative damage and inflammation, promote neuronal survival and neurogenesis”
Reviewneuron
European journal of pharmacology
Inflammation
downin reviews1
1 study
Inflammation
downin reviews1
JWH-133 decreases inflammation.
“JWH133 showed to protect neurons from oxidative damage and inflammation”
Reviewneuron
European journal of pharmacology
Neuronal oxidative damage
downin reviews1
1 study
Neuronal oxidative damage
downin reviews1
JWH-133 protects against neuronal oxidative damage.
“JWH133 showed to protect neurons from oxidative damage and inflammation”
Reviewneuron
European journal of pharmacology
Glucose uptake
upin mice1
1 study
Glucose uptake
upin mice1
JWH-133 increases glucose uptake in mice.
“both selective (JWH133 and GP1a) as well as non-selective (WIN55212-2) CB2R agonists, but not the CB1R-selective agonist, ACEA, stimulate glucose uptake”
Animals
Neuropharmacology